MDM2 and sarcoma: Of note, those three cases, including two dedifferentiated liposarcoma and one intimal sarcoma, did not receive NTRK inhibitor.3 Here, we reported one patient with sarcoma that harbors both NTRK fusion and MDM2/CDK4 amplification, which responded well to the NTRK inhibitor.